IN2013DE03033AIN3033DE2013AIN2013DE03033AIN 2013DE03033 AIN2013DE03033 AIN 2013DE03033AIN 3033DE2013 AIN3033DE2013 AIN 3033DE2013AIN 2013DE03033 AIN2013DE03033 AIN 2013DE03033A
Authority
IN
India
Prior art keywords
drug
type transdermal
dia
active
transdermal patch
Prior art date
Application number
Inventor
Chattopadhyay Pronobesh
Banerjee Subham
Ghosh Animesh
Veer Vijay
Original Assignee
Director General Defence Res & Dev Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Director General Defence Res & Dev OrgfiledCriticalDirector General Defence Res & Dev Org
Priority to IN3033DE2013priorityCriticalpatent/IN2013DE03033A/en
Publication of IN2013DE03033ApublicationCriticalpatent/IN2013DE03033A/en
A drug in adhesive (DIA) type transdermal patch for sustaining controlled drug/active release for the treatment of acetylcholine agonist (±) anatoxin-A poisoning involving a select combination of drug/active composed of eserine and pralidoxime chloride (2-PAM) which would facilitate controlled sustained release of the drug/active The DIA matrix type transdermal patch can be generally thin, circular, smooth, uniform and flexible in nature, and can be applied to 'dermal surface' including (i) intact , unbroken skin (ii) skin which is open e.g. lacerated,burned,blistered and the like and (iii) mucosal tissue. Advantageously, the DIA matrix type transdermal patch against acetylcholine agonist neutotoxin poisoning is found to be effective as non-invasive type transdermal drug sustained release delivery systems for a period of upto about 72 hours. Fig. 1